Table 1.
Incidence of VTE in patients with localized PDAC (treated with neoadjuvant chemotherapy).
| Study | Study Size | Cancer Stage, n (%) | Chemotherapy, n (%) | VTE Incidence • Stage, n (%) |
VTE incidence • Chemotherapy, n (%) |
|---|---|---|---|---|---|
| Prospective | |||||
| Frere et al., 2020 [22] | 731 | RPC: 208 (29.0) BRPC: 105 (14.6) LAPC: 212 (26.9) |
- | Total: 97 (19) • RPC: 31 (21) • BRPC: 17 (11) • LAPC: 49 (33) |
- |
| Krepline et al., 2016 [27] | 260 | RPC: 109 (42) BRPC: 151 (58) |
5-FU: 98 (37) Gemcitabine: 84 (32) Platinum agent: 110 (42) |
Total: 26 (10) • RPC: 9 (8) • BRPC: 17 (11) |
• 5-FU: 13/98 (13) • Gemcitabine: 5/84 (6) • Platinum agent: 13/110 12) |
| Walma et al., 2021 [28] | 326 | LAPC: 326 (100) | FOLFIRINOX: 252 (77) Nab-paclitaxel/gemcitabine: 33 (10) Gemcitabine: 41 (13) |
Total: 20/326 (6) | • FOLFIRINOX: 17/252 (7) • Nab-paclitaxel/ gemcitabine: 2/33 (6) • Gemcitabine: 1/41 (2) |
| Katz et al., 2016 [29] | 22 | BRPC: 22 (100) | mFOLFIRINOX: 22/22 (100) | Total: 3 (14) | • mFOLFIRINOX: 3/22 (14) |
| Retrospective | |||||
| Barreau et al., 2021 [30] | 174 | LAPC: 56 (32) | - | Total: 46 (26) LAPC: 13 (23) |
|
| Tahara et al., 2018 [31] | 27 | LAPC: 21 (78) Metastatic: 6 (22) |
FOLFIRINOX: 10 (37) Nab-paclitaxel/gemcitabine: 11 (41) |
Total: 6/27 (22) a | • FOLFIRINOX: 5 (42) • Nab-paclitaxel/gemcitabine 1 (7) |
| Hanna-Sawires et al., 2021 [32] | 361 | I: 62 (17) II: 152 (42) III: 61 (17) |
FOLFIRINOX: 6 Gemcitabine/radiotherapy: 11 |
Total: 64/361 (18) I: 7/62 (11) II: 24/152 (38) III: 9/61 (14) During neoadjuvant therapy: 2 (3) |
|
a VTE incidence for both locally advanced and metastatic PDAC, VTE incidence for only LAPC was not reported in study. BRPC: borderline resectable pancreatic cancer; LAPC: locally advanced pancreatic cancer; mFOLFIRINOX: modified FOLFIRINOX; RPC: resectable pancreatic cancer; VTE: venous thromboembolic event.